Consensus Pediatrix Medical Group, Inc.

Equities

MD

US58502B1061

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
10.03 USD +0.40% Intraday chart for Pediatrix Medical Group, Inc. +7.27% +7.85%

Evolution of the average Target Price on Pediatrix Medical Group, Inc.

Price target over the last 5 years

History of analyst recommendation changes

8a6455725a.aRsWWIS6Ui3-x0fL9FY9eKaE8LnTDdFcxHi-d0KPMvQ.ICxhIdWKP0KMgij-rBUPAODouuybPaYo_TfXRSnOU4ABXjsQ6_IIa6Gkdw~9ef85128d1e3fb5156c058a31eb81787
Jefferies Cuts Price Target on Pediatrix Medical to $9 From $11, Maintains Hold Rating MT
Deutsche Bank Trims Pediatrix Medical Group Price Target to $8 From $9, Maintains Sell Rating MT
Mizuho Trims Price Target on Pediatrix Medical to $9 From $10, Maintains Neutral Rating MT
Truist Securities Adjusts Price Target on Pediatrix Medical Group to $10 From $10.50, Keeps Hold Rating MT
UBS Initiates Coverage on Pediatrix Medical Group With Neutral Rating, $9.50 Price Target MT
Deutsche Bank Cuts Pediatrix Medical Price Target to $9 From $14, Maintains Sell Rating MT
Truist Securities Adjusts Price Target on Pediatrix Medical Group to $15 From $17, Maintains Hold Rating MT
Deutsche Bank Adjusts Pediatrix Medical Price Target to $14 From $15.50, Maintains Sell Rating MT
Credit Suisse Adjusts Price Target on Pediatrix Medical to $23 From $27, Maintains Outperform Rating MT
Credit Suisse Adjusts Pediatrix Medical Group's Price Target to $27 From $28, Keeps Outperform Rating MT
Mizuho Adjusts Price Target on Pediatrix Medical to $17 From $21, Maintains Neutral Rating MT
SVB Leerink Adjusts Price Target on Pediatrix Medical to $16 From $20, Maintains Market Perform Rating MT
Deutsche Bank Adjusts Pediatrix Medical Group Price Target to $14 From $16, Maintains Sell Rating MT
Credit Suisse Lowers Pediatrix Medical Group's Price Target to $28 from $30 After Lower-than-Expected Q2 EBITDA, Keeps Outperform Rating MT
BMO Capital Lowers Pediatrix Medical Group's Price Target to $23 From $25, Maintains Market Perform Rating MT
S&P Raises Pediatrix Medical Group Rating To 'BB-' On Better Leverage, Stable Growth; Outlook Stable MT
SVB Securities Adjusts Mednax's Price Target to $20 from $24, Keeps Market Perform Rating MT
Deutsche Bank Adjusts Price Target on Mednax to $16 From $24, Maintains Sell Rating MT
Credit Suisse Trims Mednax's PT to $30 from $31, Lowers 2022, 2023 Estimates as Q1 Underperformed Consensus on Ex-Pro Forma Basis; Maintains Outperform Rating MT
Mizuho Adjusts Mednax's Price Target to $23 from $28, Keeps Neutral Rating MT
SVB Leerink Adjusts Mednax's Price Target to $24 from $27, Keeps Market Perform Rating MT
Credit Suisse Lowers Mednax's Price Target to $31 from $32, Maintains Outperform Rating MT
Credit Suisse Lowers Mednax's PT to $32 from $33, Notes Reduced Q1 EBITDA Estimate to Reflect More Traditional Low Double Digit YoY Growth; Keeps Outperform Rating MT
Mizuho Securities Adjusts Price Target on Mednax to $28 From $32, Maintains Neutral Rating MT
SVB Leerink Adjusts Mednax's Price Target to $27 from $29, Keeps Market Perform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
10.03 USD
Average target price
9.071 USD
Spread / Average Target
-9.56%
High Price Target
10 USD
Spread / Highest target
-0.30%
Low Price Target
8 USD
Spread / Lowest Target
-20.24%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Pediatrix Medical Group, Inc.

Jefferies & Co.
Deutsche Bank Securities
Truist Securities
Mizuho Securities
UBS
Credit Suisse
SVB Securities LLC
BMO Capital
SVB Leerink
Stifel Nicolaus
Citigroup
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
  1. Stock
  2. Equities
  3. Stock Pediatrix Medical Group, Inc. - Nyse
  4. Consensus Pediatrix Medical Group, Inc.